| Variable | Northwest Territories | Nunavut | Nunavut without Iqaluit | Kitikmeot Region | Kivalliq Region | Qikiqtaaluk Region | Qikiqtaaluk Region without Iqaluit | Nunavik |
|---|---|---|---|---|---|---|---|---|
| Total births in 2009 | 739 | 816 | 701 | 114 | 245 | 457 | 342 | 250 |
| Healthy newborns* | 679.9 | 750.7 | 644.9 | 104.9 | 225.4 | 420.4 | 314.6 | 230 |
| Estimated rate of RSV-related admission per 1000 population at risk† | 16.6 | 97.8 | 111.6 | 296.1 | 112.7 | 40.3 | 49.4 | 184.1 |
| Base case: no prophylaxis, RSV-related admissions in healthy term infants admitted Jan. 1 to June 30, 2009 | ||||||||
| No. of RSV-related admissions | 8 | 52 | 51 | 22 | 18 | 12 | 11 | 30 |
| Total cost of admissions, $ | 177 256 | 2 871 137 | 2 856 561 | 1 496 365 | 1 094 603 | 280 169 | 265 593 | 632 139 |
| Scenario A: universal palivizumab prophylaxis for healthy term infants, with 96% risk reduction | ||||||||
| No. of RSV-related admissions | 0.3 | 2.1 | 2.0 | 0.9 | 0.7 | 0.5 | 0.4 | 1.2 |
| Total cost of admissions, $ | 7090 | 114 845 | 114 262 | 59 855 | 43 784 | 11 207 | 10 624 | 25 286 |
| Estimated cost of palivizumab, $ | 4 367 555 | 4 822 362 | 4 142 722 | 673 859 | 1 447 929 | 2 700 574 | 2 020 934 | 1 477 479 |
| Total cost (palivizumab + admissions), $ | 4 374 645 | 4 937 207 | 4 256 984 | 733 714 | 1 491 713 | 2 711 781 | 2 031 558 | 1 502 765 |
| Scenario A v. base case | ||||||||
| Incremental cost for RSV prophylaxis, $ | 4 197 389 | 2 066 070 | 1 400 423 | -762 652 | 397 111 | 2 431 611 | 1 765 965 | 870 625 |
| Incremental cases of RSV infection avoided | 7.7 | 49.9 | 49.0 | 21.1 | 17.3 | 11.5 | 10.6 | 28.8 |
| ICER per RSV-related admission avoided, $ | 545 115 | 41 404 | 28 580 | -36 145 | 22 954 | 211 444 | 166 600 | 30 230 |
| NNT‡ to prevent 1 RSV-related admission | 62.7 | 10.7 | 9.3 | 3.5 | 9.2 | 25.8 | 21.1 | 5.7 |
Note: ICER = incremental cost-effectiveness ratio, NNT = number needed to treat, RSV = respiratory syncytial virus.
*Estimated to be 92% of all newborns.
†Admissions for RSV infection between Jan. 1 and June 30, 2009, with population at risk of healthy term infants born after July 1, 2008, to May 31, 2009.
‡1/absolute risk reduction. Absolute risk reduction was defined as the untreated admission RSV rate - ([1 - efficacy] × untreated RSV admission rate). Untreated admission rate = number of admissions with RSV in those not treated/population at risk.